Overview

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

Status:
Terminated
Trial end date:
2021-01-20
Target enrollment:
Participant gender:
Summary
Phase 1B randomized, double-blind, placebo-controlled, two-cohort clinical trial of ABI-M201 in adult subjects with mildly-to-moderately active Ulcerative Colitis(UC) and ongoing treatment with mesalamine.
Phase:
Phase 1
Details
Lead Sponsor:
Assembly Biosciences
Collaborator:
Allergan